Inhibition of phospholipase A2 and platelet aggregation by glycyrrhizin, an antiinflammation drug.
We studied the effect of glycyrrhizin, a compound known as an anti-inflammatory and antiallergic drug, on the membrane permeability change induced by phospholipase A2 (PLA2) and on platelet aggregation. Glycyrrhizin was found to inhibit the PLA2-induced carboxyfluorescein (CF) release from D,L-dipalmitoyl phosphatidylcholine (DPPC) liposomes. Part of this inhibitory effect of glycyrrhizin on PLA2 is accounted for by the physical state of the substrate, the DPPC liposome membrane. Glycyrrhizin also inhibited collagen-induced platelet aggregation in a concentration dependent manner, which may in part account for its inhibitory effect on PLA2.
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002463:Cell Membrane Permeability / Q000187:drug effects; D003094:Collagen / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005452:Fluoresceins; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D019695:Glycyrrhizic Acid; D006801:Humans; D008081:Liposomes / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000378:metabolism; D010740:Phospholipases / Q000037:antagonists & inhibitors*; D010741:Phospholipases A / Q000037:antagonists & inhibitors*; D054467:Phospholipases A2; D010974:Platelet Aggregation / Q000187:drug effects*; D011663:Pulmonary Surfactants
D000893:Anti-Inflammatory Agents; D005452:Fluoresceins; D008081:Liposomes; D008244:Lysophosphatidylcholines; D011663:Pulmonary Surfactants; C024098:6-carboxyfluorescein; D019695:Glycyrrhizic Acid; D003094:Collagen; D010740:Phospholipases; D010741:Phospholipases A; D054467:Phospholipases A2; D006034:Glycyrrhetinic Acid